Drew Moghanaki: Not Only Humans Struggle to Confirm whether Surgery or SBRT is Better for Stage I NSCLC
Drew Moghanaki, Chief Medical Officer of Respirati and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, shared a post on X about a paper by Eun Hye Lee et al. published in Cancers:
“It’s not only humans that struggle to confirm whether surgery or SBRT is a better treatment for stage I NSCLC. Even AI-based CT modeling can’t tell the difference.”
Title: Comparison of Stereotactic Body Radiotherapy and Surgery for Stage I Lung Cancer: A Multidisciplinary Cohort Study Utilizing Propensity Score Overlap Weighting and AI-Based CT Imaging Analysis
Authors: Eun Hye Lee, Young Joo Suh, Jong Won Park, Jisu Moon, Sangjoon Park, Chang Geol Lee, Hong In Yoon, Byung Jo Park, Jin Gu Lee, Dae Joon Kim, Seung Hyun Yong, Sang Hoon Lee, Chang Young Lee, Jaeho Cho, Eun Young Kim
You can read the Full Article in Cancers.
More posts featuring Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023